B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape
Peter A. Cohen,Jennifer S. Ko,Walter J. Storkus,Christopher D. Spencer,Judy M. Bradley,Jessica E. Gorman,Dustin B. McCurry,Soroya Zorro-Manrique,Anna Lucia Dominguez,Latha B. Pathangey,Patricia Rayman,Brian I. Rini,Sandra J. Gendler,James H. Finke +13 more
TL;DR: The clinical sunitinib experience underscores that strategies for MDSC and Treg depletions must be mindful of disparities among body compartments to avoid sanctuary effects, and m-MDSCs manifesting resistance to sunit inib have the greatest potential to differentiate into tumoricidal accessory cells.
Journal ArticleDOI
Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma.
Weinan Du,Bradley M. Wright,Xin Li,James H. Finke,Brian I. Rini,Ming Zhou,H He,Priti Lal,Scott M. Welford +8 more
TL;DR: MIF is established as a protumorigenic signaling molecule that functions in an autocrine fashion to promote renal cell carcinoma and may be useful as a minimally invasive marker of disease status in CCRC.
Journal ArticleDOI
Signal integration and gene induction by a functionally distinct STAT3 phosphoform.
Matthew S. Waitkus,Unni M. Chandrasekharan,Belinda Willard,Thomas L. Tee,Jason K. Hsieh,Christopher G. Przybycin,Brian I. Rini,Paul E. DiCorleto,Paul E. DiCorleto +8 more
TL;DR: The results describe a functionally distinct, noncanonical STAT3 phosphoform that positively regulates target gene expression in a combinatorial signaling context and identify GSK-3α/β–STAT3 signaling as a potential therapeutic target in renal-cell carcinoma.
Journal ArticleDOI
GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
Tanya Das,Gaurisankar Sa,Cynthia Hilston,Daisuke Kudo,Patricia Rayman,Kaushik Biswas,Luis Molto,Ronald M. Bukowski,Brian I. Rini,James H. Finke,Charles S. Tannenbaum +10 more
TL;DR: It is demonstrated that tumor-derived TNFalpha enhances RCC apoptogenicity not only by inducing ganglioside synthesis but also by initiating receptor-dependent apoptosis in T cells in which the nuclear factor-kappaB activation pathway has been inhibited by GM1.
Journal ArticleDOI
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma
TL;DR: The current clinical data with VEGF-targeted approaches in RCC is described and plans for future development are described, including monotherapy or in combination with many trials still in progress.